Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigationa...
May 17 2021 - 4:05PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, today announced that on
Tuesday, May 18, 2021 at 8:30 am Eastern Time, the Company will
host a webcast and conference call to present 12-week expression
and safety results from Study SRP-9001-103 (Study 103), also known
as ENDEAVOR. Study 103 is the first clinical trial using Sarepta’s
commercially representative material for SRP-9001
(rAAVrh74.MHCK7.micro-dystrophin) for the treatment of Duchenne
muscular dystrophy. SRP-9001 is an investigational gene transfer
therapy intended to deliver its micro-dystrophin-encoding gene to
muscle tissue for the targeted production of the micro-dystrophin
protein.
The presentation will
be webcast live under the investor relations section of Sarepta's
website at
https://investorrelations.sarepta.com/events-presentations and
slides will be archived there following the call for one year.
Please connect to Sarepta's website several minutes prior to the
start of the broadcast to ensure adequate time for any software
download that may be necessary. The conference call may be accessed
by dialing (844) 534-7313 for domestic callers and (574) 990-1451
for international callers. The passcode for the call is 2599264.
Please specify to the operator that you would like to join the
“Sarepta-hosted Clinical Update for Micro-dystrophin Gene
Therapy.”
About Sarepta
TherapeuticsSarepta is on an urgent mission: engineer
precision genetic medicine for rare diseases that devastate lives
and cut futures short. We hold leadership positions in Duchenne
muscular dystrophy (DMD) and limb-girdle muscular dystrophies
(LGMDs), and we currently have more than 40 programs in various
stages of development. Our vast pipeline is driven by our
multi-platform Precision Genetic Medicine Engine in gene therapy,
RNA and gene editing. For more information, please
visit www.sarepta.com or follow us on Twitter, LinkedIn,
Instagram and Facebook.
Internet
Posting of InformationWe routinely post information that
may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact: Ian Estepan,
617-274-4052iestepan@sarepta.com
Media Contact: Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024